Skip to main content
Caplight Logo









Sapreme Technologies BV

Sapreme Technologies BV

Private
NetherlandsHealthcare & Life Scienceshttps://sapreme.com/

Last Round

Series A

Oct 7, 2021

Total Funding Raised

$25.01M

Company Overview

Sapreme Technologies BV is a biotechnology company that develops a proprietary endosomal escape platform to enable the cytosolic delivery of macromolecule therapeutics for genetically driven diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticsendosomal escapeintracellular deliveryantisense oligonucleotidesASOssiRNAdrug delivery platformdrug delivery techbiotechnologybiotechdrug discoverylarge-molecule therapeuticsneuromuscular diseasescardiometabolic diseasesglycosylated triterpenoids

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sapreme Technologies BV Comparables

Compare Sapreme Technologies BV with similar companies based on industry and business-model similarity.

Sapreme Technologies BV comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CyGenica
86%
Libera Bio
81%
NanoSyrinx
80%

Sapreme Technologies BV Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 7, 2021
GrantFeb 20, 2019
SeedJan 1, 2016

Key People

Founding team and executive leadership

Marco Timmers

Chief Executive Officer

Executive Team

Chris Huiskamp

Chief Financial Officer

Executive Team

Sapreme Technologies BV Investors

Notable investors and investment history

Sapreme Technologies BV investors
InvestorRounds
European UnionGrant
East Netherlands Development Agency (Oost NL)Series A
Aglaia Oncology FundsSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 7, 2021

    $17.3M round led by Aglaia Oncology Funds

  • Feb 20, 2019

    Received $8M from the European Union.

Sapreme Technologies BV Filings

Explore SEC and related filing metadata, where available.

Sapreme Technologies BV filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Sapreme Technologies BV's valuation, stock price, and market status.

Is Sapreme Technologies BV a public or private company?

Sapreme Technologies BV is a private company.

What is the current stock price of Sapreme Technologies BV?

Sapreme Technologies BV is a private company with no public stock price. No recent secondary market data is available.

How much is Sapreme Technologies BV worth (valuation)?

Valuation information for Sapreme Technologies BV is not publicly available.

Can I buy Sapreme Technologies BV stock?

Sapreme Technologies BV shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Sapreme Technologies BV's last funding round?

Sapreme Technologies BV's most recent funding round was Series A on October 7, 2021.

Who are the main investors in Sapreme Technologies BV?

Key investors in Sapreme Technologies BV include Aglaia Oncology Funds.

Will Sapreme Technologies BV IPO soon?

No public IPO plans have been announced for Sapreme Technologies BV.

How can I track Sapreme Technologies BV secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sapreme Technologies BV's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNetherlands
Employee Range13
Year Founded2016
Last FundingOct 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?